Rheumatology Experts & Viewpoints
- Update On Lupus: Treatment Reality Check
- Retooling for an Aging America
- Tumor Necrosis Factor Inhibitors vs New Biologics for the Treatment of Inflammatory Joint Diseases: Evidence on Safety and Efficacy -- An Expert Interview With Jonathan Kay, MD
- The ACR-EULAR Collaboration: An Expert Interview With David A. Fox, MD
- EULAR 2008 Highlights From Daniel Furst, MD
- Physicians for Sale: How Medical Professional Organizations Exploit Their Members
- Building Physician Connectivity for e-Prescribing
- What Is the Risk of Osteonecrosis in Long-term Survivors of Cancer?
- New Options With IL-6 Antagonists: Treating the Systemic Manifestation of RA: An Expert Interview With Joel Kremer, MD
- EULAR 2008 Highlights From Ronald F. van Vollenhoven, MD, PhD
POLL
A new bill in Congress would send trained clinicians into doctors’ offices with independent data about the relative benefits, risks, and costs of drugs; some research suggests that such "academic detailing" reduces potential prescribing bias from the influence of drug company reps. What effect do you think such a program would have?